Susy S Hota1, Salman Surangiwala1, Aimee S Paterson1, Bryan Coburn1, Susan M Poutanen1. 1. Affiliations: Department of Infection Prevention and Control (Hota), University Health Network; Department of Medicine (Hota, Coburn), University of Toronto; Department of Microbiology (Surangiwala, Paterson, Poutanen), University Health Network/Sinai Health System; Toronto General Hospital Research Institute (Coburn); Department of Laboratory Medicine and Pathobiology (Poutanen), University of Toronto, Toronto, Ont.
Abstract
BACKGROUND: There is growing evidence that fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection, but little guidance exists for implementation of FMT programs. The objective of this study is to describe the program characteristics and protocols of 9 planned or operating FMT programs in the Southern Ontario Fecal Microbiota Transplantation (SOFT) Movement, to help guide future FMT program implementation. METHODS: A 59-item survey was administered electronically to clinical leads of the SOFT Movement on June 2, 2016. The survey evaluated 7 domains: FMT program characteristics, FMT recipients, donor screening/selection, transplant manufacturing, FMT administration, good manufacturing procedures/biosafety procedures and infection-control procedures. We used descriptive statistics to analyze quantitative data. RESULTS: All 9 programs responded to the survey: 6 were active, 1 had FMT standard operating procedures developed but did not have clinical experience, and 2 were in the process of forming FMT programs. All 6 active programs performed FMT in adult patients with C. difficile infection. About 1300 FMT procedures were performed between 2003 and 2016. Five of the 6 operating programs administered the preparation via enema. Programs were driven primarily by physicians. All programs used universal FMT donors and followed Health Canada's screening guidelines, with considerable variability in screening frequency (every 3-6 mo) and modality. Locations for transplant preparation and manufacturing protocols varied across programs. Stool mass for FMT ranged from 20 g to 150 g, and transplant volume ranged from 25 mL to 300 mL. INTERPRETATION: The experience of this high-volume regional FMT network highlights current challenges in FMT program development, including a high reliance on physicians and the costly nature of donor screening. Standardization and optimization through development of regional centres of excellence for FMT donor recruitment and administration should be explored. Copyright 2018, Joule Inc. or its licensors.
BACKGROUND: There is growing evidence that fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficileinfection, but little guidance exists for implementation of FMT programs. The objective of this study is to describe the program characteristics and protocols of 9 planned or operating FMT programs in the Southern Ontario Fecal Microbiota Transplantation (SOFT) Movement, to help guide future FMT program implementation. METHODS: A 59-item survey was administered electronically to clinical leads of the SOFT Movement on June 2, 2016. The survey evaluated 7 domains: FMT program characteristics, FMT recipients, donor screening/selection, transplant manufacturing, FMT administration, good manufacturing procedures/biosafety procedures and infection-control procedures. We used descriptive statistics to analyze quantitative data. RESULTS: All 9 programs responded to the survey: 6 were active, 1 had FMT standard operating procedures developed but did not have clinical experience, and 2 were in the process of forming FMT programs. All 6 active programs performed FMT in adult patients with C. difficileinfection. About 1300 FMT procedures were performed between 2003 and 2016. Five of the 6 operating programs administered the preparation via enema. Programs were driven primarily by physicians. All programs used universal FMT donors and followed Health Canada's screening guidelines, with considerable variability in screening frequency (every 3-6 mo) and modality. Locations for transplant preparation and manufacturing protocols varied across programs. Stool mass for FMT ranged from 20 g to 150 g, and transplant volume ranged from 25 mL to 300 mL. INTERPRETATION: The experience of this high-volume regional FMT network highlights current challenges in FMT program development, including a high reliance on physicians and the costly nature of donor screening. Standardization and optimization through development of regional centres of excellence for FMT donor recruitment and administration should be explored. Copyright 2018, Joule Inc. or its licensors.
Authors: Christine H Lee; Theodore Steiner; Elaine O Petrof; Marek Smieja; Diane Roscoe; Anouf Nematallah; J Scott Weese; Stephen Collins; Paul Moayyedi; Mark Crowther; Mark J Ropeleski; Padman Jayaratne; David Higgins; Yingfu Li; Neil V Rau; Peter T Kim Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Samuel P Costello; Emily C Tucker; Justin La Brooy; Mark N Schoeman; Jane M Andrews Journal: Clin Infect Dis Date: 2015-11-30 Impact factor: 9.079
Authors: E M Terveer; Y H van Beurden; A Goorhuis; J F M L Seegers; M P Bauer; E van Nood; M G W Dijkgraaf; C J J Mulder; C M J E Vandenbroucke-Grauls; H W Verspaget; J J Keller; E J Kuijper Journal: Clin Microbiol Infect Date: 2017-05-19 Impact factor: 8.067
Authors: Josbert J Keller; Rogier E Ooijevaar; Christian L Hvas; Elisabeth M Terveer; Simone C Lieberknecht; Christoph Högenauer; Perttu Arkkila; Harry Sokol; Oleksiy Gridnyev; Francis Mégraud; Patrizia K Kump; Radislav Nakov; Simon D Goldenberg; Reetta Satokari; Sergiy Tkatch; Maurizio Sanguinetti; Giovanni Cammarota; Andrey Dorofeev; Olena Gubska; Gianluca Laniro; Eero Mattila; Ramesh P Arasaradnam; Shiv K Sarin; Ajit Sood; Lorenza Putignani; Laurent Alric; Simon M D Baunwall; Juozas Kupcinskas; Alexander Link; Abraham G Goorhuis; Hein W Verspaget; Cyriel Ponsioen; Georgina L Hold; Herbert Tilg; Zain Kassam; Ed J Kuijper; Antonio Gasbarrini; Chris J J Mulder; Horace R T Williams; Maria J G T Vehreschild Journal: United European Gastroenterol J Date: 2021-03-09 Impact factor: 4.623